NCT00472719View on ClinicalTrials.gov

Safety of and Immune Response to a DNA HIV Vaccine Followed By Boosting With One of Two Serotypes of Adenoviral Vector HIV Vaccine in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

July 31, 2008

Study Completion Date

January 31, 2013

Conditions
HIV Infections
Interventions
BIOLOGICAL

VRC-HIVADV027-00-VP

Adenoviral vector booster vaccine

BIOLOGICAL

VRC-HIVADV038-00-VP

Adenovirus vector booster vaccine

BIOLOGICAL

VRC-HIVDNA044-00-VP

Experimental, multiclade, multigene HIV DNA vaccine

Trial Locations (7)

10065

New York Blood Center CRS, New York

14642

University of Rochester Vaccines to Prevent HIV Infection CRS, Rochester

35294

Alabama Vaccine CRS, Birmingham

94143

Bridge HIV CRS, San Francisco

10032-3732

Columbia P&S CRS, New York

37232-2582

Vanderbilt Vaccine (VV) CRS, Nashville

98109-1024

Seattle Vaccine and Prevention CRS, Seattle

All Listed Sponsors
collaborator

HIV Vaccine Trials Network

NETWORK

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00472719 - Safety of and Immune Response to a DNA HIV Vaccine Followed By Boosting With One of Two Serotypes of Adenoviral Vector HIV Vaccine in Healthy Adults | Biotech Hunter | Biotech Hunter